MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD BDRX 深 沪
已收盘 01-30 16:00:00 美东时间
1.77
-0.070
-3.80%
华盛通- 最 高1.79
- 今 开1.79
- 成交量 13.32万股
- 最 低 1.71
- 昨 收 1.84
- 总市值 109.65万
- 52周最高 92.00
- 市盈率 静 --
- 换手率 21.50%
- 52周最低 1.71
- 委 比 8.13%
- 总股本 61.95万
- 历史最高 159417654.2112
- 量 比 0.79
- 振 幅 4.35%
- 历史最低 1.71
- 每 手 1
- 风险率 10.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biodexa Pharmaceuticals Prices $10M Public Offering, Selling 157,000 ADS Units At $3.28 And 2.89M Pre-Funded Units
Biodexa Announces Pricing of $10 Million Public OfferingBiodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for
2025-12-18 21:40
Biodexa Prices $10M Public Offering
Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs,
2025-12-18 21:38
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 38.7% to...
2025-12-16 20:05
Biodexa Pharmaceuticals Advances Serenta Trial and Secures Financial Backing
An announcement from Biodexa Pharmaceuticals ( ($BDRX) ) is now available. Biod...
2025-09-12 21:33
Biodexa Pharmaceuticals GAAP EPS of -£0.0002
Biodexa Pharmaceuticals press release (NASDAQ:BDRX): 1H GAAP EPS of -£0.0002. Net cash used in operating activities (after changes in working capital) in 1H25 was £3.30 million (1H24: £4.81 million). ...
2025-09-12 20:43
Biodexa Pharmaceuticals Begins Phase 3 Trial for FAP Treatment
Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an announcement. On August 18...
2025-08-18 20:57
Biodexa Pharmaceuticals Implements ADR Ratio Change
Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an update. On July 31, 2025, ...
2025-07-31 21:59
Biodexa Pharma Advances Development eRapa, Oral Tablet Formulation Of Rapamycin, To Treat FAP Non-Surgically
Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company, reports making significant progress in developing eRapa, an oral tablet formulation of rapamycin, to treat FAP non-surgically. eRapa
2025-07-28 19:10
Biodexa Pharma Files CTA With EMA For Serenta Trial In Patients With Familial Adenomatous Polyposis
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial inFamilial Adenomatous Polyposis (FAP)Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical
2025-07-14 20:35
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has named its upcoming Phase 3 study for Familial Adenomatous Polyposis (FAP) "Serenta" and launched a dedicated website, www.serentatrial.com, to provide information for patients and healthcare professionals. Serenta highlights Biodexa's commitment to supporting the FAP community. The study focuses on eRapa, an oral mTOR inhibitor designed to address the poor bioavailability and toxicity of existing rapamycin forms. Addit...
2025-06-23 12:30
